Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nova Mentis Life Sciences Corp (OP: NMLSF ) 0.0058 -0.0017 (-22.67%) Streaming Delayed Price Updated: 10:48 AM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Nova Mentis Life Sciences Corp Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More April 24, 2023 LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... Via Benzinga Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism April 20, 2023 The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started < Via Benzinga Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More February 21, 2023 Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... Via Benzinga Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder February 14, 2023 Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a... Via Benzinga Nova Mentis Is Looking To Treat Autism With Psilocybin April 07, 2022 Nova Mentis Life Science Corp. (OTCQB: NMLSF) and the private college Toronto Institute of Pharmaceutical Technology have signed a ... Via Benzinga First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval December 27, 2022 The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a... Via Benzinga Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project December 06, 2022 Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... Via Benzinga Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial November 30, 2022 Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB: NMLSF) and Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Sciences Inc. Via Benzinga Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial November 17, 2022 Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science... Via Benzinga Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin September 30, 2022 Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops Via Benzinga Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn September 29, 2022 Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry,... Via Benzinga Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application September 29, 2022 Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)... Via Newsfile New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details September 17, 2022 Canadian-based psychedelics company Nova Mentis Life Science Corp. Via Benzinga Nova Mentis Completes Production of Psilocybin Microdose Capsules September 15, 2022 Vancouver, British Columbia--(Newsfile Corp. - September 15, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)... Via Newsfile More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases June 16, 2022 The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB: NMLSF) is filing new provisional patent applications to the U.S. Via Benzinga Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies June 08, 2022 The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. Via Benzinga Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened June 07, 2022 Nova Mentis Life Science Corp. (OTCQB: NMLSF), also known as NOVA, a biotech company developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, recently... Via Benzinga Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study February 22, 2022 Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. ... Via Benzinga This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism February 16, 2022 Nova Mentis Life Science Corp (OTCQB: NMLSF) is a biotechnology company focused on psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. The... Via Benzinga Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market February 08, 2022 Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Via Benzinga Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis January 27, 2022 The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada Via Benzinga Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval November 08, 2021 Detroit Decriminalizes Psychedelics Via Benzinga Exposures Product Safety Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent October 26, 2021 The Week In Psychedelics Via Benzinga Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation October 18, 2021 The Week In Psychedelics Via Benzinga There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are October 13, 2021 Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.